BIOGEN INC

NASDAQ: BIIB (Biogen Inc.)

Last update: 2 days ago, 10:03AM

246.11

-5.30 (-2.11%)

Previous Close 251.41
Volume 294,686
Price / Earnings (Forward) 16.28
Price / Sales 3.66
Price / Book 1.98
52 Weeks Range
160.36 (-34%) — 261.00 (6%)
Profit Margin 15.07%
Operating Margin (TTM) 28.05%
Diluted EPS (TTM) 10.12
Quarterly Revenue Growth (YOY) 6.10%
Quarterly Earnings Growth (YOY) -38.90%
Total Debt/Equity (MRQ) 39.00%
Current Ratio (MRQ) 1.44
Operating Cash Flow (TTM) 2.58 B
Levered Free Cash Flow (TTM) 3.43 B
Return on Assets (TTM) 5.43%
Return on Equity (TTM) 9.19%

AIStockmoo Score

0.7
Dearer than its usual valuation. info
Earns below its cost of capital. Returns on capital falling. info
Low debt. Positive cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Uptrend over the past year. Trading near its 52-week high. info
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Holdings' Sentiment info NA
Institutions net +0.95% of shares in their latest 13F filings: 549 holders increased, 440 decreased (quarter to 30 Sep 2026). info
Short interest -4.8% from 31 Aug to 30 Oct 2026, 4 days to cover (FINRA). info
Insider Activity info NA
Market environment cautious. info
Sector outperforming the market.
The pillars disagree, so the score is softened.
Earnings per share have mostly fallen. Earnings have been uneven. info
Above its medium-term trend line. info
Price is high against its 52-week average. info
Short-term momentum fading. info
Price is near support. Levels trending up. info
Final Score 0.68
Show all

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Bullish
Drug Manufacturers - General (Global) Mixed Bullish
Stock Biogen Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
BIIB - - - 1.98 0.7
GRFS - 1.08% - 0.900 1.1
SNY 112 B 5.21% 23.14 1.37 0.3
AMGN 236 B 2.28% 25.25 16.73 1.0
GILD 206 B 1.95% - 16.08 0.6
MIRA 15 M - 36.83 3.72 -1.0

Select this tab to load the latest available analysis.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Mid Value
% Held by Insiders 0.19%
% Held by Institutions 92.79%

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 116.68%

Positions Holders Shares
Increased 549 10,525,966
Decreased 440 9,615,344
New 113 1,651,262
Sold out 80 1,158,196

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 5,453,103 4.0
15 Oct 2026 5,500,386 4.4
30 Sep 2026 5,965,892 4.9
15 Sep 2026 5,817,797 7.6
31 Aug 2026 5,726,631 8.7
14 Aug 2026 5,190,555 6.1

FINRA short interest via Nasdaq, reported twice a month.

10 Positive 1 Negative 8 Neutral
Date Type Details
19 Nov 2026 Yahoo Finance Should Biogen Stock Holders Look At Amgen Instead?
Today's big story: Could Anthropic Stock Fall 25…
19 Nov 2026 Yahoo Finance Biogen reports two-year Phase II data for diranersen in Alzheimer’s
The trial evaluated diranersen in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer's.
18 Nov 2026 Yahoo Finance What Could Biogen (BIIB) Gain From Its New Protein Degrader Research Deal?
Biogen (NasdaqGS:BIIB) said it has entered a research collaboration with TRIMTECH Therapeutics to develop small molecule protein degraders for neurodegenerative diseases. The agreement focuses on discovering targeted degraders that aim to remove disease related proteins in conditions such as…
18 Nov 2026 Yahoo Finance New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced new three-year real-world findings of 560 patients across 13 U.S. clinical sites from the largest analysis of the ongoing Lecanemab in Early Alzheimer's Disease (LEADER) study* reported to date. New LEADER findings from a pre-specified…
18 Nov 2026 Yahoo Finance Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
Biogen (NasdaqGS:BIIB) reported positive two year Phase 2 CELIA results for diranersen in early Alzheimer’s disease. The firm released new five year data for lecanemab that showed sustained clinical benefit and reduced progression risk in treated patients. Management framed these late stage…
18 Nov 2026 Yahoo Finance FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
18 Nov 2026 Yahoo Finance Biogen (BIIB) Stock May Be 49% Undervalued After Fresh Alzheimer’s Data
Biogen has had a strong run over the past year, helped by fresh Alzheimer’s data and new product formats. This puts the focus squarely on whether the current share price lines up with the cash the business can generate. With the stock now around US$250.79 at the last close, the key issue is how…
18 Nov 2026 Yahoo Finance Biogen (BIIB) After Fresh Alzheimer’s Data, Is The Valuation Story Still Compelling?
Biogen (BIIB) is back in the Alzheimer’s spotlight after new five year data for lecanemab and two year Phase 2 results for diranersen outlined sustained clinical benefits and supportive safety signals. Investors have been rewarding this stream of Alzheimer’s updates, with Biogen’s share price…
17 Nov 2026 Yahoo Finance Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Biogen (NASDAQ:BIIB) expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return to revenue growth, President and Head of North America Alisha Alaimo said at a Jefferies conference…
17 Nov 2026 Yahoo Finance Biogen: 3 Key Takeaways for Long-Term Investors
Late-stage trials could reshape the rare disease franchise, but the real story is whether the pipeline matters at all.
17 Nov 2026 Yahoo Finance Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
CARLSBAD, Calif., November 17, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in…
16 Nov 2026 Yahoo Finance New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril antibody, were presented at the 19th Clinical Trials on Alzheimer's…
16 Nov 2026 Yahoo Finance TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease
CAMBRIDGE, England, November 16, 2026--TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and…
12 Nov 2026 Yahoo Finance LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home AdministrationTOKYO and CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of “LEQEMBI®” (generic name…
10 Nov 2026 Yahoo Finance Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion Costs
Two neighbors get the same Alzheimer's diagnosis and the same prescription, yet only one can count on a manageable bill. A missed registry rule and a closed enrollment window could decide who pays, and the clock runs out December 7…
09 Nov 2026 Yahoo Finance ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP Phase 3 PHOENYCS GO data for the first time found greater proportions of patients receiving DZP plus…
05 Nov 2026 Yahoo Finance Biogen’s (BIIB) Pipelines Offers Multiple Potential Catalysts
Baron Capital, an investment management company, released its Q3 2026 investor letter for the “Baron Health Care Fund”. The letter can be downloaded here. During the quarter ended September 30, 2026, Baron Health Care Fund® advanced 4.02%, underperforming the Russell 3000 Health Care Index’s 6.19%…
05 Nov 2026 Yahoo Finance Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
TORONTO, November 05, 2026--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth, subject to individual plan eligibility and reimbursement…
05 Nov 2026 Yahoo Finance Is Alzheimer’s Data Altering The Investment Case For Biogen (BIIB)?
Biogen recently shared new clinical, biomarker and safety data on its Alzheimer’s portfolio at the CTAD 2026 conference, including extended Phase 2 CELIA results for diranersen and long term analyses for lecanemab. The breadth of readouts, from 96 week diranersen extension data to real world…
02 Nov 2026 Yahoo Finance Should You Buy The Dip In Alnylam Stock?
For questions about this article or underlying research, email [email protected].
30 Oct 2026 Yahoo Finance What Just Happened To Alnylam Stock?
For questions about this article or underlying research, email [email protected].
29 Oct 2026 Yahoo Finance Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says
Biogen (BIIB) has swung back to growth as shown by its solid Q3 results, RBC analysts wrote in a not…
29 Oct 2026 Yahoo Finance Alphabet downgraded, eBay upgraded: Wall Street's top analyst calls
Alphabet downgraded, eBay upgraded: Wall Street's top analyst calls…
29 Oct 2026 Yahoo Finance Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's diseaseLecanemab presentations will highlight new long-term and real-world evidence, including initial five-year…
Show more

Technical Setup Medium

Trend order
Slope
Entry
Volume
In an uptrend: the price is above its moving averages, and they are rising. It is close to them.
Nearest support: 236.41 – 244.86 · strong level · tested often, may give way
Nearest resistance: 252.58 – 262.83 · moderate level · tested often, may give way

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria